The National Comprehensive Cancer Network Oncology Research Program (ORP) announced a collaboration with Pfizer Global Medical Grants (Pfizer) that awards new grants to advance the understanding of the mechanisms of action, underlying biology, and clinical activity of talazoparib in prostate cancer.
“This research will involve innovative investigations of talazoparib and foster the development of PARP inhibitors in prostate cancer,” said Crystal S. Denlinger, MD, FACP, Senior Vice President, Chief Scientific Officer, NCCN. “Congratulations to all of the grantees. We look forward to results that may guide the development of talazoparib alone or in combination with other therapies in prostate cancer.”
“We have seen incredible progress in the treatment of prostate cancer over the last decade, however, there continues to be a need for ongoing innovation to support improved patient outcomes,” said Dr. Roxanne Ferdinand, Genitourinary (GU) Global Franchise Medical Lead, Pfizer Oncology. “Pfizer is committed to collaborating with professional organizations like NCCN to fund research that helps to advance our understanding of how different therapies can address unmet needs. We look forward to seeing how these efforts help to progress patient care.”
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected priority areas will focus on clinical development of talazoparib combinations, defining predictive biomarkers of clinical benefit. The studies are set to be completed within two years. Collectively, the total amount of grants awarded for this study are approximately $1.5 million.
The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions.
The National Comprehensive Cancer Network is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.